natgillin/translations-raw huggingface dataset:
Neželeni učinki so razvrščeni po organskih sistemih in po pogostnosti z upoštevanjem naslednjega dogovora: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
The adverse reactions are classified by System Organ Class and frequency, using the following convention: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki so razvrščeni po oznakah pogostnosti, najpogostejši najprej, upoštevaje naslednji dogovor: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Neželeni učinki v preglednicah, o katerih so poročali, so dogodki, ki so se pojavili pri 0,1 % s pramipeksolom zdravljenih bolnikov ali več, in o katerih so poročali pomembno pogosteje pri bolnikih, ki so jemali pramipeksol, kot pri tistih, ki so jemali placebo, ali pa je bil dogodek ocenjen kot klinično pomemben.
The adverse drug reactions reported in these tables are those events that occurred in 0.1% or more of patients treated with pramipexole and were reported significantly more often in patients taking pramipexole than placebo, or where the event was considered clinically relevant.
Neželeni učinki zaradi hipokalciemije
Hypocalcaemia-related ADRs
Neželeni učinki, ki se lahko pojavijo, vendar njihova pogostnost ni znana (ni je mogoče oceniti iz razpoložljivih podatkov), so:
Side effects that may be seen but the frequency is not known (frequency cannot be estimated from the available data) are:
Neželeni učinki, ki se pogosto (pri več kot 1 od 100 bolnikov) pojavijo pri zdravljenju z zdravilom INOmax, so: nizek krvni tlak, pljuča brez zraka ali kolaps pljuč.
Side effects that are commonly seen (affects more than 1 user in 100) in association with INOmax therapy include: low blood pressure, airless or collapsed lung.
Neželeni učinki, ki se pogosto (pri več kot 1 od 100 bolnikov) pojavijo pri zdravljenju z zdravilom INOmax, so: nizek krvni tlak, pljuča brez zraka ali kolaps pljuč;
Side effects that are commonly seen (affects more than 1 user in 100) in association with INOmax therapy include: low blood pressure, airless or collapsed lung.
Neželeni učinki, ki se pojavijo občasno (med 1 od 100 bolnikov in 1 od 1000 bolnikov), so: povišana raven methemoglobina, kar zmanjša zmožnost prenosa kisika.
Side effects that may be seen, but uncommonly (affects between 1 user in 100 and 1 user in 1000) are: increase in methaemoglobin, thus reduced oxygen carrying capacity.
Neželeni učinki, o katerih so pri uporabi pemetrekseda, tako v primeru monoterapije kot v kombinaciji z drugimi zdravili, najpogosteje poročali, so bili povezani z zavrtjem delovanja kostnega mozga, kar se je izrazilo kot anemija, nevtropenija, levkopenija, trombocitopenija; in s toksičnostjo za prebavila, kar se je izrazilo kot anoreksija, slabost, bruhanje, diareja, zaprtje, faringitis, mukozitis in stomatitis.
The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leucopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis.
Neželeni učinki, pri katerih pogostnosti ni možno oceniti
Frequency not known side effects
Neželenih učinkov po prekinitvi zdravljenja z zdravilom Teysuno ni.
There are no side effects caused by stopping treatment with Teysuno.
Nežiaduce reakcie hlásené u ≥ 5 % pacientov v klinickom skúšaní ET743-OVA-301
Adverse reactions reported in ≥ 5% of patients in clinical trial ET743-OVA-301
Nežiaduce reakcie ohlásené u ≥ 1 % pacientov so sarkómom mäkkých tkanív v klinických skúškach.
Adverse reactions reported in ≥ 1% of patients with soft tissue sarcoma in clinical trials.
Nežiaduce účinky
Undesirable effects
Nežiaduce účinky sú uvedené v každej frekvenčnej skupine v poradí klesajúcej závažnosti.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Nežno premešajte.
Gently mix.
Nežno si umivajte zobe in lahkotno se useknite.
Brush your teeth and blow your nose gently.
Nežno stisnite očiščeno kožo s palcem in kazalcem.
Gently pinch the cleaned skin between your thumb and index finger.
Nežvýkejte je, nedělte ani nedrťte.
Do not chew, divide or crush.
Nežádoucí účinek
Adverse reaction
Nežádoucí účinek
Not known
Nežádoucí účinek léku
Adverse Drug Reaction
Nežádoucí účinky
Adverse Reactions
Nežádoucí účinky hlášené při použití přípravku Intuniv
Adverse Drug Reactions Reported with Intuniv
Nežádoucí účinky hlášené při použití přípravku Intuniv
Orthostatic hypotension
Nežádoucí účinky jsou rozděleny podle orgánových systémů a četnosti: velmi časté ( ≥ 1/10), časté (≥ 1/100 až < 1/10), méně časté (≥ 1/1 000 až < 1/100) a vzácné (≥1/10 000 až 1/1000).
Adverse reactions are listed by system organ class and frequency: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100) and rare (≥1/10,000 to 1/1,000).
Nežádoucí účinky můžete hlásit také přímo prostřednictvím národního systému hlášení nežádoucích účinků uvedeného v Dodatku V. Nahlášením nežádoucích účinků můžete přispět k získání více informací o bezpečnosti tohoto přípravku.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Nežádoucí účinky somnolence a sedace se vyskytovaly převážně na počátku léčby a obvykle trvaly 2-3 týdny, v některých případech déle.
The adverse reactions somnolence and sedation occurred predominantly at the start of treatment and may typically last for 2-3 weeks and longer in some cases.
nežádoucí účinky spojené s
tenofovir-associated adverse
NHL със засягане на ЦНС
NHL with CNS involvement
Ni dokazov, da bi bili potrebni posebni previdnostni ukrepi.
There is no evidence to suggest that any extra precautions are needed.
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 (razen cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel.
Ni farmakokinetičnih interakcij s selegilinom in levodopo.
There is no pharmacokinetic interaction with selegiline and levodopa.
Ni podatkov o vplivu palonosetrona na plodnost.
There are no data concerning the effect of palonosetron on fertility.
Ni podatkov za bolnike s končno ledvično okvaro na hemodializi.
No data are available for patients with end stage renal disease undergoing haemodialysis.
Ni pomembno.
Not relevant.
Ni poročil o primerih prevelikega odmerjanja.
No case of overdose has been reported.
Ni posebnih pogojev shranjevanja.
No special storage conditions.
Ni smiselno.
Not applicable
Ni uveljavljenega antidota za preveliko odmerjanje agonistov dopamina.
There is no established antidote for overdose of a dopamine agonist.
Ni verjetno, da bi ustekinumab z IL-12 in/ali IL-23 prispeval k citotoksičnemu učinku na receptorske celice, posredovanemu preko komplementa ali protiteles.
Thus, ustekinumab is not likely to contribute to complement- or antibody-mediated cytotoxicity of cells with IL-12 and/or IL-23 receptors.
Ni zadostnih podatkov o uporabi dušikovega oksida pri nosečnicah.
There are no adequate data from the use of nitric oxide in pregnant women.
Ni zadostnih podatkov o uporabi ustekinumaba pri nosečnicah.
There are no adequate data from the use of ustekinumab in pregnant women.
Ni znanega antidota za preveliko odmerjanje.
There is no known antidote available in case of overdose.
Ni znano ali zdravilo STELARA lahko vpliva na imunoterapijo proti alergiji.
It is not known whether STELARA may affect allergy immunotherapy.
Ni znano, ali bo zdravilo Palonosetron Hospira povzročilo škodljive učinke med uporabo v nosečnosti.
It is not known whether Palonosetron Hospira will cause any harmful effects when used during pregnancy.
Ni znano, ali se dušikov oksid izloča v materino mleko.
It is unknown whether nitric oxide is excreted in human milk.
Ni znano, ali se pemetreksed izloča v materino mleko, in neželenih reakcij za dojenčka ne moremo izključiti.
It is not known whether pemetrexed is excreted in human milk, and adverse reactions on the suckling child cannot be excluded.
Ni znano, ali se Teysuno/presnovki izločajo v materino mleko.
It is not known whether Teysuno or its metabolites are excreted in human milk.
Ni znano, ali se ustekinumab izloča v materino mleko pri človeku.
It is unknown whether ustekinumab is excreted in human breast milk.
Ni znano, ali se ustekinumab sistemsko absorbira po zaužitju.
It is not known if ustekinumab is absorbed systemically after ingestion.
Ni znano, ali se zoledronska kislina izloča v materino mleko.
It is not known whether zoledronic acid is excreted into human milk.
Ni znano, ali zdravilo Palonosetron Hospira prehaja v materino mleko.
It is not known if Palonosetron Hospira is found in breast milk.
Ni znano: hude krvavitve (povezane s trombocitopenijo).
Not known: severe bleeding (associated with thrombocytopenia)
Nicméně je třeba se jakémukoli možnému riziku vyhnout (viz bod 6.6).
However, any possible risk should be avoided (see section 6.6).
Nicméně klopidogrel byl podáván společně s ASA po dobu jednoho roku (viz bod 5.1).
However, clopidogrel and ASA have been administered together for up to one year (see section 5.1).
Nicméně pacienti se středně těžkou (třída B podle Child-Pugha) až těžkou (třída C podle Child-Pugha) poruchou funkce jater nesmí atazanavir užívat.
However, atazanavir must not be used in patients with moderate (Child-Pugh Class B) to severe (Child-Pugh Class C) hepatic impairment.
Nicobrand Limited 189 Castleroe Road, Coleraine
Nicobrand Limited 189 Castleroe Road Coleraine
Nie je k dispozícii špecifické antidotum pre extravazáciu trabektedínu.
There is no specific antidote for extravasation of trabectedin.
Nie je známe, či sa trabektedín vylučuje do materského mlieka.
It is not known whether trabectedin is excreted in human milk.
Nie sú k dispozícii dostatočné klinické údaje o gravidných ženách vystavených účinku lieku.
No sufficient clinical data on exposed pregnancies are available.
Nie sú k dispozícii údaje porovnávajúce Yondelis+PLD s režimom založeným na platine u pacientov citlivých na platinu.
No data are available comparing Yondelis+PLD to a platinum-based regimen in platinum-sensitive patients.
Niektoré z príznakov alebo znakov extravazácie nemusia byť viditeľné do niekoľkých hodín potom, ako došlo k extravazácii.
Some of the symptoms or signs of extravasation may not be visible until several hours after it occurred.
Nieuwe Donk 9, ETTEN-LEUR, 4879AC, Нидерландия
Nieuwe Donk 9, ETTEN-LEUR, 4879AC, Netherlands
Nikolaus Dürkopp Straße 4a D-33602 Bielefeld Германия
Hälsa Pharma GmbH Nikolaus Dürkopp Straße 4a D-33602 Bielefeld Germany
Nikoli ne smete izvleči bata.
Do not pull back on the plunger at any time
Nimenrix
88.6
Nimenrix
Nimenrix 1 dose
Nimenrix
vaccine
Nimenrix 1 доза
Nimenrix
Nimenrix [2 795 (95% CI: 2 393; 3 263)] в сравнение с групата на MenC-CRM ваксината [5 292 (95% CI: 3 815; 7 340)].
CI: 89.2; 98.8) respectively], GMTs were lower for the Nimenrix group [2795 (95% CI: 2393; 3263)] versus the MenC-CRM vaccine [5292 (95% CI: 3815; 7340)].
Nimenrix е ваксина, която помага за предпазване от инфекции, причинявани от бактерии, наречени “Neisseria meningitidis" типове A, C, W-135 и Y.
Nimenrix is a vaccine which helps protect against infections caused by bacteria (germs) called “Neisseria meningitidis" types A, C, W-135 and Y.
Nimenrix е ваксина.
Nimenrix is a vaccine.
Nimenrix е показан за активна имунизация срещу инвазивни менингококови заболявания, причинявани от Neisseria meningitidis групи A, C, W-135 и Y, при лица на възраст на и над 12 месеца.
Nimenrix is indicated for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.
Nimenrix е прах и разтворител за инжекционен разтвор.
Nimenrix is a powder and a solvent for solution for injection.
Nimenrix е сравнен с няколко други подобни ваксини срещу N. meningitidis при хора на възраст 12 месеца и по-големи.
Nimenrix was compared with several other similar vaccines against N. meningitidis in people aged 12 months or more.
Nimenrix индуцира производството на бактерицидни антитела срещу капсулни полизахариди от група A, C, W-135 и Y, при измерване в изпитвания със заешки комплемент (rSBA) или с човешки комплемент (hSBA).
Nimenrix induces the production of bactericidal antibodies against capsular polysaccharides of group A, C, W-135 and Y when measured by assays using either rabbit complement (rSBA) or human complement (hSBA).
Nimenrix може да се използва и за усилване на нивото на защита при хора, които вече са били ваксинирани с Nimenrix или с друга менингококова ваксина.
Nimenrix may also be used as a booster vaccine in people who have already been vaccinated with Nimenrix or another meningococcal vaccine, to reinforce the level of protection.
Nimenrix може да се прилага едновременно и с комбинирани ваксини срещу дифтерия, тетанус и коклюш (безклетъчни), включително и с DTaP ваксини, комбинирани с хепатит В, инактивиран полиовирус или Haemophilus influenzae тип b, като DTaP-HBV-IPV/Hib ваксина и 13-валентна пневмококова конюгатна ваксина през втората година от живота.
Nimenrix can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis vaccines, including combination DTaP vaccines with hepatitis B, inactivated polio or Haemophilus influenzae type b, such as DTaP-HBV-IPV/Hib vaccine and 13-valent pneumococcal conjugate vaccine in the second year of life.
Nimenrix може да се прилага едновременно с всяка от следните ваксини: ваксини срещу хепатит А (HAV) и хепатит В (HBV), ваксина срещу морбили, паротит и рубеола (MMR), ваксина срещу морбили, паротит, рубеола и варицела (MMRV), 10-валентна пневмококова конюгатна ваксина или сезонна ваксина срещу грип без адювант.
Nimenrix can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.
Nimenrix може да се прилага на възрастни, юноши и деца на възраст над 12 месеца.
Nimenrix may be given to adults, adolescents and children over the age of 12 months.
Nimenrix може да се прилага по едно и също време с други ваксини, като ваксини срещу хепатит А и хепатит В, ваксина срещу морбили, паротит и рубеола, ваксина срещу морбили, паротит, рубеола и варицела, 10-валентна пневмококова конюгатна ваксина или сезонна ваксина срещу грип без адювант.
Nimenrix can be given at the same time as other vaccines such as hepatitis A and hepatitis B vaccines, measles-mumps-rubella vaccine, measles-mumps-rubella-varicella vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.
Nimenrix може да се приложи като бустер доза при лица, получили предшестваща първична ваксинация с Nimenrix или други конюгатни или неконюгатни полизахаридни менингококови ваксини (вж. точки 4.4 и 5.1).
Nimenrix may be given as a booster dose in individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccine (see sections 4.4 and 5.1).
Nimenrix може да се приложи като бустер доза при лица, получили предшестваща първична ваксинация с Nimenrix или други конюгатни или неконюгатни полизахаридни менингококови ваксини (вж. точки 4.4 и 5.1).
Nimenrix may be given as a booster dose in individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines (see sections 4.4 and 5.1).
Nimenrix прах и разтворител за инжекционен разтвор в ампула Конюгатна ваксина срещу менингококи от групи A, C, W-135 и Y
Nimenrix powder and solvent for solution for injection in ampoule Meningococcal group A, C, W-135 and Y conjugate vaccine
Nimenrix прах и разтворител за инжекционен разтвор в ампула Конюгатна ваксина срещу менингококи от групи A, C, W-135 и Y (Meningococcal group A, C, W-135 and Y conjugate vaccine)
Nimenrix powder and solvent for solution for injection in ampoule Meningococcal group A, C, W-135, and Y conjugate vaccine
Nimenrix прах и разтворител за инжекционен разтвор в предварително напълнена спринцовка
Nimenrix powder and solvent for solution for injection in pre-filled syringe
Nimenrix прах и разтворител за инжекционен разтвор в предварително напълнена спринцовка Конюгатна ваксина срещу менингококи от групи A, C, W-135 и Y (Meningococcal group A, C, W-135 and Y conjugate vaccine)
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal group A, C, W-135, and Y conjugate vaccine
Nimenrix предизвиква бактерицидни отговори срещу всичките четири групи, които са сходни по отношение на % с rSBA титър ≥ 8 и GMT след една или две дози (Таблица 3).
Nimenrix elicited bactericidal responses against all four groups that were similar in terms of % with rSBA titre ≥8 and GMT after one or two doses (Table 3).
Nimenrix се използва за защита на възрастни, юноши и деца на възраст от 12 месеца срещу инвазивни менингококови заболявания, причинени от четири групи бактерии N. meningitidis (групи A, C, W-135 и Y).
Nimenrix is used to protect adults, adolescents and children from the age of 12 months against invasive meningococcal disease caused by four groups of the bacterium N. meningitidis (group A, C, W-135, and Y).
Nimenrix се понася добре и CHMP счита, че може да се прилага безопасно заедно с други рутинно прилагани ваксини при различни възрастови групи.
Nimenrix is well tolerated and the CHMP considered that it can be safely given together with other routinely used vaccines in the different age groups.
Nimenrix се прилага съгласно наличните официални препоръки.
Nimenrix should be used according to available official recommendations.
Nimenrix съдържа малки количества полизахариди (захари), извлечени от четирите групи бактерии N. meningitidis: A, C, W135 и Y. Тези полизахариди са пречистени и след това
Nimenrix contains small amounts of polysaccharides (sugars) extracted from the four groups of the
Nimvastid 1,5 mg
Nimvastid 1.5 mg
Nimvastid 1,5 mg таблетки, диспергиращи се в устата ривастигмин
Nimvastid 1.5 mg orodispersible tablets Rivastigmine
Nimvastid 1,5 mg твърди капсули Ривастигмин
Nimvastid 1.5 mg hard capsules Rivastigmine
Nimvastid 1,5 mg твърди капсули, които съдържат бял до почти бял прах, имат жълта капачка и жълто тяло.
Nimvastid 1.5 mg hard capsules, which contain a white to almost white powder, have a yellow cap and yellow body.
Nimvastid 3 mg
Nimvastid 3mg (on carton label only)
Nimvastid 3 mg таблетки, диспергиращи се в устата
Nimvastid 3 mg orodispersible tablets
Nimvastid 3 mg таблетки, диспергиращи се в устата ривастигмин
Nimvastid 3 mg orodispersible tablets Rivastigmine
Nimvastid 3 mg твърди капсули Ривастигмин
Nimvastid 3 mg hard capsules Rivastigmine
Nimvastid 4,5 mg
Nimvastid 4.5 mg
Nimvastid 4,5 mg
Nimvastid 4.5 mg (on carton label only)
Nimvastid 4,5 mg таблетки, диспергиращи се в устата ривастигмин
Nimvastid 4.5 mg orodispersible tablets Rivastigmine
Nimvastid 4,5 mg твърди капсули Ривастигмин
Nimvastid 4.5 mg hard capsules Rivastigmine
Nimvastid 6 mg
Nimvastid 6 mg (on carton label only)
Nimvastid 6 mg таблетки, диспергиращи се в устата ривастигмин
Nimvastid 6 mg orodispersible tablets Rivastigmine
Nimvastid 6 mg твърди капсули Ривастигмин
Nimvastid 6 mg hard capsules Rivastigmine
Nimvastid е „генерично лекарство“.
Nimvastid is a ‘generic medicine’.
Nimvastid може да взаимодейства с антихолинергични лекарства (лекарства, използвани за облекчаване на коремни болки или спазми, за лечение на болест на Паркинсон, или за предотвратяване на болест на пътуването).
Nimvastid might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson’s disease or to prevent travel sickness).
Nimvastid не трябва да се използва по време на бременност, освен ако е абсолютно необходимо.
Nimvastid should not be used during pregnancy unless clearly necessary.
Nimvastid се използва за лечение на възрастни пациенти с лека до умерено тежка Алцхаймерова деменция, прогресивно мозъчно заболяване, което постепенно засяга паметта, интелектуалните способности и поведението.
Nimvastid is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Nimvastid съдържа сорбитол Е 420.
Nimvastid contains sorbitol E420
NIS-LL промяна от изходната стойност
NIS-LL change from BL
Niso pa študije prikazale neposrednega ali posrednega škodljivega učinka na plodnost pri samcih.
However, these studies did not indicate direct or indirect harmful effects with respect to male fertility.
Niso znane
Incompatibilities
Nitroimidazoli lahko zmanjšajo očistek 5-FU in zato povišajo ravni 5-FU v plazmi.
However, nitromidazoles may reduce clearance of 5-FU and thus increase plasma levels of 5-FU.
Nitroimidazoli, vključno z metronidazolom in mizonidazolom
Nitroimidazoles, including metronidazole and misonidazole
Nivestim
Strength
Nivestim 12 MU/ 0,2 ml инжекционен/инфузионен разтвор Nivestim 30 MU/ 0,5 ml инжекционен/инфузионен разтвор Nivestim 48 MU/ 0,5 ml инжекционен/инфузионен разтвор
Nivestim 12 MU/ 0.2 ml solution for injection/infusion Nivestim 30 MU/ 0.5 ml solution for injection/infusion Nivestim 48 MU/ 0.5 ml solution for injection/infusion
Nivestim 12 MU/0,2 ml
Nivestim 12 MU/0.2 ml
Nivestim 12 MU/0,2 ml инжекционен/инфузионен разтвор
Nivestim 12 MU/ 0.2 ml solution for injection/infusion
Nivestim 12 MU/0,2 ml инжекционен/инфузионен разтвор
Nivestim 12 MU/ 0.2 ml solution for injection/infusion,
Nivestim 12 MU/0,2 ml инжекционен/инфузионен разтвор Nivestim 30 MU/0,5 ml инжекционен/инфузионен разтвор Nivestim 48 MU/0,5 ml инжекционен/инфузионен разтвор Филграстим (Filgrastim)
Nivestim 12 MU/0.2 ml solution for injection/infusion Nivestim 30 MU/0.5 ml solution for injection/infusion Nivestim 48 MU/0.5 ml solution for injection/infusion Filgrastim
Nivestim 12 MU/0,2 ml инжекционен/инфузионен разтвор Филграстим
Nivestim 12 MU/0.2 ml solution for injection/infusion Filgrastim
Nivestim 12 MU/0,2 ml инжекционен/инфузионен разтвор: всяка предварително напълнена спринцовка съдържа 12 милиона единици (MU), 120 микрограма филграстим в 0,2 ml (отговарящо на 0,6 mg/ml).
Nivestim 12 MU/ 0.2 ml solution for injection/ infusion: each pre-filled syringe contains 12 million units (MU), 120 micrograms of filgrastim in 0.2 ml (corresponding to 0.6 mg/ml).
Nivestim 30 MU/0,5 ml
Nivestim 30 MU/0.5 ml
Nivestim 30 MU/0,5 ml инжекционен/инфузионен разтвор
Nivestim 30 MU/ 0.5 ml solution for injection/infusion
Nivestim 30 MU/0,5 ml инжекционен/инфузионен разтвор Филграстим
Nivestim 30 MU 0.5 ml solution for injection/infusion Filgrastim
Nivestim 30 MU/0,5 ml инжекционен/инфузионен разтвор, Nivestim 48 MU/0,5 ml инжекционен/инфузионен разтвор
Nivestim 30 MU/ 0.5 ml solution for injection/infusion, Nivestim 48 MU/ 0.5 ml solution for injection/infusion